Clinical Trial: Cancer

ALTEO5N1: Long-Term Follow-up protocol (PRO00001591)

Full Name

ALTEO5N1: UMBRELLA LONG-TERM FOLLOW-UP PROTOCOL

 

Description

For those who agree to participate, the COG institution where the participant received care will provide information to the COG Data Center that will assist the Long-Term Follow-up Center (LTFC) in maintaining contact with the participant. Information collected can include: the participant's full name, date of birth, social security number (is requested, not required), gender, place of birth, drivers license number (is requested, not required), the COG protocol in which the participant was enrolled, the participants language preference, address and telephone number, race/ethnic group, email address, the full name of the participant's parents, the participant's parent's address and telephone number, their parent's date of birth, their parent's email address, their parent's language preference, and their parent's social security numbers (is requested, not required). The researchers would also like to collect the name address and telephone number of a family member (preferably grandparent) or close friend who can give the participant's contact information if the LTFC has trouble contacting the participant. The data center at COG will then provide this information to the LTFC at the University of Southern California in Los Angeles, California. After the LTFC receives the information, the LTFC will send mailings to participants from time to time. The mailings will explain the purpose of the LTFC. Included in the mailing will be a Participant Update Form, which will include the information the COG institution provided to the LTFC at the time of the participant's enrollment on this study and will include any updates that the participant submitted with subsequent mailings. The mailings will also include a few questions about the participant's health status and the contact information for the participant's current primary healthcare provider. Participants will do the following: read over the information; fix any information that is no longer correct; complete and update the Participant Update Form; return their responses to the LTFC.

 

Eligibility

Inclusion Criteria

Must be enrolled on a frontline COG therapeutic trial for treatment of primary malignancy and is nearing completion of or has completed protocol treatment (within the past 180 days), or 

Must have been enrolled on a COG (or Legacy Group) therapeutic or non-therapeutic trial targeted for long-term follow-up by ALTE05N1